Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care-Reference-Cited by-同舟云学术

Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care

Published:2024-09-07 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Gye Amy^ORCID,De Abreu Lourenco Richard,Goodall Stephen

Funder

Novartis Australia

University of Technology Sydney

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40273-024-01430-7.pdf

Reference47 articles.

1. Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1–204.

2. Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661–8.

3. Gye AGS, De Abreu LR. A systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients. Value Health. 2021;25(1):47–58. https://doi.org/10.1016/j.jval.2021.07.008.

4. Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy. 2019;17(6):771–80. https://doi.org/10.1007/s40258-019-00513-3.

5. Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care; a critical review. 2017. Accessed Accessed 27 January 2021 at http://nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf.